This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) Beats Q1 Earnings Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 2.95% and 2.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Merit Medical (MMSI) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Merit Medical (MMSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Is Henry Schein (HSIC) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
by Zacks Equity Research
Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.
Henry Schein (HSIC) Meets Q4 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Dentsply International (XRAY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Henry Schein (HSIC) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Henry Schein (HSIC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
HSIC Gears Up for Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive sales in both its businesses in the fourth quarter of 2024, along with a positive pace of recovery from the cyber incident.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HSIC Stock Might Rise Following the Acquisition of Acentus
by Zacks Equity Research
Henry Schein completes the acquisition of Acentus, which expands the former's Home Solution business.
Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes
by Zacks Equity Research
Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC owing to the performance of its dental business.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Up 6.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?
by Zacks Equity Research
COO's fiscal fourth-quarter results are likely to reflect segmental strength.
Macro Challenges to Hurt Patterson Companies' Q2 Earnings?
by Zacks Equity Research
PDCO's fiscal second-quarter results are likely to reveal a decline in both the Dental and Animal Health segments, reflecting challenges like moderating traffic to clinics.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
by Zacks Equity Research
Henry Schein inked a new agreement to acquire Acentus to enhance its ability to deliver CGM products directly to patients' homes.
Company News for Nov 19, 2024
by Zacks Equity Research
Companies In The News Are: TWST, CVS, OKLO, HSIC.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.